Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. European Heart Journal 2018;39:3021–104. https://doi.org/10.1093/EURHEARTJ/EHY339.
DOI: 10.1093/EURHEARTJ/EHY339
Guideline for the pharmacological treatment of hypertension in adults n.d. https://www.ncbi.nlm.nih.gov/books/NBK573631/https://www.ncbi.nlm.nih.gov/books/NBK573631/
Guideline for the pharmacological treatment of hypertension in adults n.d. https://www.ncbi.nlm.nih.gov/books/NBK573631/https://www.ncbi.nlm.nih.gov/books/NBK573631/
Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский Кардиологический Журнал 2020;25:3786. https://doi.org/10.15829/1560-4071-2020-3-3786.
DOI: 10.15829/1560-4071-2020-3-3786
CEL,LJF,SB,AKC,WCC,JAC,etal.FinalReportofaTrialof Intensive versus Standard Blood-Pressure Control. N Engl J Med 2021;384:1921–30. https://doi.org/10.1056/NEJMOA1901281.
DOI: 10.1056/NEJMOA1901281
Savarese G, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131–42. https://doi.org/10.1016/J.JACC.2012.10.011.
DOI: 10.1016/J.JACC.2012.10.011
Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–25. https://doi.org/10.1161/CIRCULATIONAHA.105.595496.
DOI: 10.1161/CIRCULATIONAHA.105.595496
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887–98. https://doi.org/10.1056/NEJMOA0801369.
DOI: 10.1056/NEJMOA0801369
Kaplan NM. Vascular outcome in type 2 diabetes: an ADVANCE? Lancet 2007;370:804–5. https://doi.org/10.1016/S0140-6736(07)61304-X.
DOI: 10.1016/S0140-6736(07)61304-X
Бойцов СА, Баланова ЮА, Шальнова СА, Деев АД, Артамонова ГВ, Гатагонова ТМ и соавт. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилактика 2014;13:4–14. https://doi.org/10.15829/1728-8800-2014-4-4-14.
DOI: 10.15829/1728-8800-2014-4-4-14
Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart 2019;105:98–105. https://doi.org/10.1136/HEARTJNL-2018-313599.
DOI: 10.1136/HEARTJNL-2018-313599
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403–19. https://doi.org/10.1161/HYPERTENSIONAHA.108.189141.
DOI: 10.1161/HYPERTENSIONAHA.108.189141
Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71-82. https://doi.org/10.1001/JAMA.2012.113905.
DOI: 10.1001/JAMA.2012.113905
Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005;3:15–29. https://doi.org/10.1586/14779072.3.1.15.
DOI: 10.1586/14779072.3.1.15
Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol 1996;12:1191–6. https://doi.org/10.21608/zjps.2005.177781.
DOI: 10.21608/zjps.2005.177781
Afshin A, Sur PJ, Fay KA, Cornaby L, Ferrara G, Salama JS, et al. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019;393:1958-72. https://doi.org/10.1016/S0140-6736(19)30041-8.
DOI: 10.1016/S0140-6736(19)30041-8
Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 2011;24:843–53. https://doi.org/10.1038/AJH.2011.115.
DOI: 10.1038/AJH.2011.115
Roush GC, Sica DA. Diuretics for Hypertension: A Review and Update. Am J Hypertens 2016;29:1130–7. https://doi.org/10.1093/AJH/HPW030.
DOI: 10.1093/AJH/HPW030
Akram J, Sheikh UE, Mahmood M, Donnelly R. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: The NATIVE study. Current Medical Research and Opinion 2007;23:2929–36. https://doi.org/10.1185/030079907X242674.
DOI: 10.1185/030079907X242674
Czernichow S, Ninomiya T, Huxley R, Kengne AP, Batty GD, Grobbee DE, et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension 2010;55:1193–8. https://doi.org/10.1161/HYPERTENSIONAHA.109.140624.
DOI: 10.1161/HYPERTENSIONAHA.109.140624
Дубинина ЕА, Коростовцева ЛС, Ротарь ОП, Кравченко СО, Бояринова МА, Орлов АВ, et al. Взаимосвязь риска нарушений дыхания во сне и сердечно-сосудистого риска. Кардиоваскулярная Терапия и Профилактика 2016;15:46–52. https://doi.org/10.15829/1728-8800-2016-6-46-52.
DOI: 10.15829/1728-8800-2016-6-46-52
McNicholas WT, Bonsignore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007;29:156–78. https://doi.org/10.1183/09031936.00027406.
DOI: 10.1183/09031936.00027406
Deflandre E, Gerdom A, Lamarque C, Bertrand B. Understanding Pathophysiological Concepts Leading to Obstructive Apnea. Obesity Surgery 2018;28:2560–71. https://doi.org/10.1007/S11695-018-3325-6.
DOI: 10.1007/S11695-018-3325-6
Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis 2009;51:371–80. https://doi.org/10.1016/J.PCAD.2008.02.004.
DOI: 10.1016/J.PCAD.2008.02.004
Labarca G, Schmidt A, Dreyse J, Jorquera J, Enos D, Torres G, et al. Efficacy of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) and resistant hypertension (RH): Systematic review and meta-analysis. Sleep Med Rev 2021;58. https://doi.org/10.1016/J.SMRV.2021.101446.
DOI: 10.1016/J.SMRV.2021.101446
Ferrari R, Pasanisi G, Notarstefano P, Campo G, Gardini E, Ceconi C. Specific properties and effect of perindopril in controlling the renin- angiotensin system. Am J Hypertens 2005;18:142–54. https://doi.org/10.1016/J.AMJHYPER.2005.05.037.
DOI: 10.1016/J.AMJHYPER.2005.05.037
Свиряев Ю., Звартау Н., Ротарь О., Коростовцева Л., Конради А., Калинкин А. Использования СРАР-терапии на фоне медикаментозного лечения артериальной гипертензии у больных с синдромом апноэ во сне. Артериальная гипертензия. 2008;14(3):264-269. https://doi.org/10.18705/1607-419X-2008-14-3-264-269.
DOI: 10.18705/1607-419X-2008-14-3-264-269
Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Gulsin GS, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension 2017;70:1042-8. https://doi.org/10.1161/HYPERTENSIONAHA.117.09631.
DOI: 10.1161/HYPERTENSIONAHA.117.09631
Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid- lowering therapy. Arch Intern Med 2005;165:1147–52. https://doi.org/10.1001/ARCHINTE.165.10.1147.
DOI: 10.1001/ARCHINTE.165.10.1147
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta- analysis. Hypertension 2010;55:399–407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816.
DOI: 10.1161/HYPERTENSIONAHA.109.139816